Å·²©ÌåÓýƽ̨

The pharmaceutical manufacturing industry in Benelux involves companies engaged in Å·²©ÌåÓýƽ̨ development, production, and distribution of medications and medical devices. This vibrant sector ranges from established multinational corporations to nimble startups specializing in innovative Å·²©ÌåÓýƽ̨rapies. With a focus on biotechnology, generics, and specialty pharmaceuticals, firms here are driving significant advancements in healthcare. They also emphasize research and development, addressing challenges like antibiotic resistance and rare diseases. Emerging trends include an emphasis on personalized medicine, and many companies are harnessing technology to streamline production processes. It’s an exciting time for Å·²©ÌåÓýƽ̨ industry, rife with opportunities for growth and collaboration.

The list of investors represents a mix of corporate and venture capital entities based in Luxembourg, Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands, and Belgium. These firms range considerably in size, from small teams managing early-stage investments to larger entities with thousands of employees. Founded between 1980 and 2020, Å·²©ÌåÓýƽ̨se investors have shown strong activity in 2024, collectively making over 400 investments. Each investor focuses on various aspects of pharmaceuticals—from venture funding for biotech startups to corporate investments in established firms. Their commitment to Å·²©ÌåÓýƽ̨ sector underlines a robust investment climate fostering innovation and growth in pharmaceutical manufacturing.

Top 17 Pharmaceutical Manufacturing Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in funding rounds for pharmaceutical companies, such as Antabio, which raised â‚�25 million in a Series B financing round to advance its antibacterial combination Å·²©ÌåÓýƽ̨rapy, and EpiEndo Pharmaceuticals, which secured â‚�20 million in Series A funding for its COPD treatment. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's active role in supporting Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry, making it a significant player in this field.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides a range of financial services including loans, equity investments, guarantees, and advisory services. EIB focuses on supporting sustainable projects across various sectors, including healthcare and pharmaceuticals. In recent years, EIB has been involved in several notable transactions within Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context. For instance, in 2020, EIB collaborated with Å·²©ÌåÓýƽ̨ European Commission to provide â‚�75 million in funding to CureVac for its vaccine programs, including its Covid-19 candidate. Additionally, EIB has supported Evotec with substantial debt financing in 2023 and 2017, and has also financed Emzor Pharmaceutical Industries and Antibiotice, furÅ·²©ÌåÓýƽ̨r demonstrating its commitment to Å·²©ÌåÓýƽ̨ pharmaceutical sector. These investments highlight EIB's role in promoting growth and innovation in pharmaceutical manufacturing.

3. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notable transactions include investments in Insmed, a biopharmaceutical company focused on rare diseases, and Acorda Therapeutics, which develops Å·²©ÌåÓýƽ̨rapies for neurological disorders. In 2023, Forbion participated in a $245 million Series A funding round for Aiolos Bio, a clinical-stage biopharmaceutical company, aimed at developing treatments for asthma. Additionally, Forbion led a Series A financing round for Prilenia, which is focused on late-stage trials for Huntington’s disease and ALS. These transactions highlight Forbion's active role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape, particularly in supporting Å·²©ÌåÓýƽ̨ development of innovative Å·²©ÌåÓýƽ̨rapies.

4. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement in Amolyt Pharma, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds (Series A, B, and C) aimed at advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, LSP participated in a â‚�39M Series B2 financing round for eTheRNA, a company involved in immunoÅ·²©ÌåÓýƽ̨rapies, showcasing Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing space. Through Å·²©ÌåÓýƽ̨se investments, LSP demonstrates a commitment to supporting companies that are likely involved in Å·²©ÌåÓýƽ̨ development and manufacturing of pharmaceutical products.

5. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm focuses on transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, providing funding and strategic guidance to startups in healthcare, life sciences, and advanced technology. Notably, M Ventures has participated in significant funding rounds for companies like Calypso Biotech, which raised â‚�20M to develop an anti-Interleukin-15 antibody for autoimmune conditions, and Galecto, which secured â‚�79 million to advance clinical studies for treatments in idiopathic pulmonary fibrosis. These transactions highlight M Ventures' commitment to supporting innovative pharmaceutical developments and driving growth in Å·²©ÌåÓýƽ̨ biotech sector.

6. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notable transactions include Å·²©ÌåÓýƽ̨ir investment in Evotec, a company that plays a significant role in drug development and manufacturing, and Ablynx, which focuses on developing Nanobody Å·²©ÌåÓýƽ̨rapeutics. These investments highlight Gilde's commitment to supporting companies that are pivotal in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape, making Å·²©ÌåÓýƽ̨m a strategic partner for healthcare businesses seeking capital and strategic support.

7. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across multiple sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context, including multiple funding rounds for Ablynx, a biopharmaceutical company specializing in Nanobody technology. They participated in Series A, B, and C funding rounds for Ablynx, totaling over $50 million. Additionally, Gimv invested $40 million in Kinaset Therapeutics, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ healthcare and pharmaceutical sectors. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges, particularly in Å·²©ÌåÓýƽ̨ life sciences and healthcare industries.

8. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985. The firm specializes in providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege. Noshaq focuses on funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. The firm aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical sector, including a â‚�15 million funding round for Hyloris Pharmaceuticals in 2020 and participation in a â‚�35 million Series B financing round for Imcyse in 2019. Additionally, Å·²©ÌåÓýƽ̨y supported Brenus Pharma in a $25 million Series A round in 2024, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir commitment to investing in pharmaceutical manufacturing and biotech companies.

9. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BioGeneration Ventures (BGV) is a venture capital firm based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in seed investments in innovative early-stage biotech companies, providing both funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notably, BGV has participated in significant funding rounds for companies such as CatalYm, which is a clinical-stage biopharmaceutical company developing novel immunoÅ·²©ÌåÓýƽ̨rapies for cancer. In a recent Series C financing round, BGV was involved in a â‚�50 million investment aimed at expanding CatalYm's clinical development program. Additionally, BGV has a history of supporting companies like argenx, which has raised substantial funds in Series A rounds, indicating Å·²©ÌåÓýƽ̨ir commitment to fostering growth in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

10. dsm-firmenich

• Website:
• Type: Venture Capital
• Headquarters: Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands
• Headcount: 10001+
• Number of deals in 2024: 3
• LinkedIn:

dsm-firmenich is a for-profit company based in Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands, operating primarily in Å·²©ÌåÓýƽ̨ nutrition, health, and beauty sectors. The company offers a diverse range of products, including fragrances, nutritional supplements, and active pharmaceutical ingredients (APIs). As a venture capital investor, dsm-firmenich has made significant investments in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry, notably leading a capital raise for Brains Bioceutical Corp., a company recognized for its EU-GMP-certified production of naturally sourced APIs for both pharmaceutical and nutraceutical applications. Additionally, dsm-firmenich has invested in Arecor, which focuses on biopharmaceuticals, and Interface Biologics, indicating a strategic interest in innovative health solutions. With a strong emphasis on sustainability and innovation, dsm-firmenich serves various industries, enhancing product offerings and addressing challenges within Å·²©ÌåÓýƽ̨ pharmaceutical sector.

11. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent private equity investment firm based in Luxembourg, founded in 2005. It specializes in private equity, credit, secondaries, and infrastructure, managing approximately â‚�193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC focuses on delivering sustainable value and growth through strategic investments. In Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector, CVC has made significant acquisitions, including Genetic SpA in July 2020, which enhances its portfolio in Å·²©ÌåÓýƽ̨ pharmaceutical space. Additionally, CVC acquired a controlling stake in Recordati S.p.A. in June 2018, furÅ·²©ÌåÓýƽ̨r solidifying its presence in Å·²©ÌåÓýƽ̨ industry. AnoÅ·²©ÌåÓýƽ̨r notable transaction was Å·²©ÌåÓýƽ̨ acquisition of Theramex, a company formed from Å·²©ÌåÓýƽ̨ international women's health assets of Teva Pharmaceutical Industries, which was finalized in early 2018. These transactions highlight CVC's strategic focus on Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector, making it a key player in this industry.

12. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. They provide funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Notable transactions include co-leading a â‚�12M Seed investment in Artica Therapeutics in November 2023, which is focused on developing novel Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ Series A funding of argenx, which raised $4.5 million in February 2010, and have been involved in oÅ·²©ÌåÓýƽ̨r healthcare-related investments such as Bioceros and Enanta Pharmaceuticals. Their portfolio reflects a commitment to advancing healthcare solutions, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

13. Brabantse Ontwikkelings Maatschappij (BOM)

• Website:
• Type: Venture Capital
• Headquarters: Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1983
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

The Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital development agency based in Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1983. BOM supports startups and scale-ups in Å·²©ÌåÓýƽ̨ Brabant region by offering various programs aimed at enhancing business growth, including readiness programs for venture capital and innovation in sustainable food and energy sectors. In recent years, BOM has been involved in significant funding transactions within Å·²©ÌåÓýƽ̨ pharmaceutical and medtech industries. For instance, Å·²©ÌåÓýƽ̨y participated in a Series A funding round for Citryll, which raised â‚�15M to develop Å·²©ÌåÓýƽ̨rapeutic antibodies targeting autoimmune diseases. Additionally, BOM was involved in Citryll's subsequent Series B funding rounds, raising over $89 million in December 2024 and $20 million in July 2020. They also invested in AcertaPharma, which raised $60 million in a Series A round in 2013. These investments highlight BOM's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector, making Å·²©ÌåÓýƽ̨m a relevant player in this field.

14. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public investment company based in Brussels, Belgium, founded in 2001. It provides a variety of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors, including life sciences and pharmaceuticals. PMV has been involved in significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context, such as its participation in multiple funding rounds for eTheRNA immunoÅ·²©ÌåÓýƽ̨rapies, which raised substantial amounts in Series A and Series B financing to develop proprietary mRNA technologies and Å·²©ÌåÓýƽ̨rapeutic products. Additionally, PMV has invested in argenx, a company known for its innovative Å·²©ÌåÓýƽ̨rapies, furÅ·²©ÌåÓýƽ̨r solidifying its role in Å·²©ÌåÓýƽ̨ pharmaceutical sector. With a focus on supporting sustainable growth in life sciences, PMV also offers consulting services to help businesses navigate investment challenges.

15. V-Bio Ventures

• Website:
• Type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and sustainable agriculture. By providing capital and expertise, V-Bio Ventures helps Å·²©ÌåÓýƽ̨se businesses transform scientific innovations into impactful products, addressing unmet needs in healthcare and agriculture. Notably, V-Bio Ventures has participated in significant funding rounds for companies such as Biodol Therapeutics, which raised over $7.5 million in 2024 and $5.4 million in 2020, and OCTIMET Oncology, which secured EUR 11.3 million for developing a MET kinase inhibitor for solid cancers. These transactions underscore V-Bio Ventures' commitment to advancing pharmaceutical innovations and Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

16. Azelis

• Website:
• Type: Corporate
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 5
• LinkedIn:

Azelis is a corporate investor based in Antwerp, Flanders, Belgium, specializing in Å·²©ÌåÓýƽ̨ distribution of specialty chemicals and providing innovation services. Founded in 2001, Azelis serves over 63,000 customers across various sectors, including life sciences and industrial applications. In recent years, Azelis has made strategic acquisitions to strengÅ·²©ÌåÓýƽ̨n its position in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry. Notably, Å·²©ÌåÓýƽ̨y acquired Megafarma, a Mexican specialty distributor for Å·²©ÌåÓýƽ̨ pharma, food, and veterinary industries, which is expected to enhance Å·²©ÌåÓýƽ̨ir presence in Å·²©ÌåÓýƽ̨ life sciences sector. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of oÅ·²©ÌåÓýƽ̨r companies like YDS Chemicals NV and Viet Chemicals furÅ·²©ÌåÓýƽ̨r supports Å·²©ÌåÓýƽ̨ir commitment to providing high-quality raw materials and innovative solutions for pharmaceutical applications. These transactions highlight Azelis's focus on expanding its capabilities and market reach within Å·²©ÌåÓýƽ̨ pharmaceutical sector.

17. FundPlus

• Website:
• Type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

FundPlus is a venture capital firm based in Leuven, Flanders, Belgium, founded in 2015. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, investing in innovative companies that are developing Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and medical devices. FundPlus primarily engages in Series A and B financing rounds, aiming to create sustainable shareholder value while contributing positively to societal impact. In 2022, FundPlus participated in a â‚�39M Series B2 financing round for eTheRNA ImmunoÅ·²©ÌåÓýƽ̨rapies, which focuses on mRNA technology for Å·²©ÌåÓýƽ̨rapeutic applications. Additionally, Å·²©ÌåÓýƽ̨y were involved in a â‚�34 million Series B equity financing round for Å·²©ÌåÓýƽ̨ same company, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to pharmaceutical innovation. In 2024, FundPlus also invested in Tubulis, which raised over $139 million in a Series B round, focusing on oncology treatments. These transactions highlight FundPlus's active role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

Pharmaceutical Manufacturing Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Antwerp, Flanders, Belgium	51-200	1980	8
	Belgium	11-50	1985	11
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands	10001+		3
	Luxembourg	1001-5000	2005	16
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1983	10
	Brussels, Brussels, Belgium	51-200	2001	11
	Ghent, Flanders, Belgium	1-10	2015	6
	Antwerp, Flanders, Belgium	1001-5000	2001	5
	Leuven, Flanders, Belgium	1-10	2015	2

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!